Luxury and lifestyle hospitality: Why investors are checking in
Macro resilience meets micro precision
Despite persistent headwinds like elevated interest rates and global uncertainty, hospitality investment, particularly in premium segments, continues to exhibit robust performance. Recent data from STR and Tourism Economics forecasts RevPAR (revenue per available room) growth between 3% and 3.7% year-over-year through 2025 for upper-upscale and luxury hotels, surpassing other hotel classes. CoStar's Q1 2025 analysis further confirms the trend, indicating demand growth in luxury hotels exceeding midscale assets by 50-100 basis points. These figures underscore a distinct market bifurcation and highlight why astute investors are targeting premium hospitality.
Introducing DLLX: Built for the next generation of travel
Recognizing the structural evolution of hospitality, Driftwood recently launched DLLX, a division explicitly designed to harness opportunities in luxury hotels, lifestyle-driven assets and branded residences. Under the leadership of Alinio Azevedo, former CEO of Aspen Hospitality, DLLX targets more than $3 billion in deployments across carefully selected, high-growth domestic and international markets. This strategic initiative aligns with a global surge in high-net-worth and ultra-high-net-worth travelers seeking curated experiences and branded assurance.
DLLX's differentiation lies in its integration with Driftwood Hospitality Management (DHM), which currently operates over 80 properties nationwide. This close partnership ensures end-to-end operational excellence from asset acquisition to ongoing management, driving investor returns through operational efficiency and data-driven insights.
Case studies: Strategic execution from the Space Coast to Miami
Two marquee projects illustrate Driftwood's strategic precision and innovative execution:
Westin Cocoa Beach Resort, Spa, and Conference Center: A 502-room beachfront development on Florida's thriving Space Coast. Once complete, Driftwood will control approximately 62% of the beachfront inventory in a region anticipated to benefit from more than 300 annual rocket launches by 2028. Early identification of this market opportunity positions Driftwood for sustained, demand-driven outperformance.
Dream Riverside Wharf, Miami: A Hyatt-branded lifestyle property situated on Miami's revitalized riverfront, featuring 165 keys and curated experiential amenities. Positioned in an Opportunity Zone and EB-5 eligible region, this project exemplifies how strategic site selection, demographic appeal and capital structure ingenuity, converge to create multi-dimensional investor benefits.
Vertical integration: Driftwood's structural edge
Driftwood Capital's unique advantage resides in its comprehensive control over the investment lifecycle — from origination, underwriting, and development to long-term operational management. Leveraging its proprietary Domino technology platform, Driftwood centralizes real-time operational data, enhancing decision-making agility and transparency. This structural integration optimizes cost efficiencies, execution velocity and capital deployment precision, providing investors with institutional-quality access to premium hospitality investments.
Investable, experiential, integrated: Hospitality's new paradigm
Today's hospitality investment is more than a traditional real estate play. Instead, it's a bet on evolving consumer behaviors and demographic trends. Branded residences, for example, achieve consistent premiums exceeding 30% over non-branded counterparts, reflecting an ongoing shift toward curated lifestyle experiences and brand assurances.
With over $5 billion in historical transactions and a robust institutional syndication network, Driftwood Capital and its DLLX division are positioned to lead this new hospitality paradigm. For investors seeking durable yields, capital preservation and strategic upside in an inflation-resilient asset class, DLLX offers more than just thematic appeal. It represents structural alignment with the future of hospitality investment.
Learn how Driftwood Capital is turning strategic insight into actionable opportunities by visiting driftwoodcapital.com or contacting us directly at .
With over $5 billion in transactions to date, Driftwood's platform is built on direct ownership, disciplined underwriting, and operational expertise. Driftwood's business model provides accredited investors (as defined in Rule 501 under Regulation D) access to institutional-quality hotel assets or capital solutions on a direct deal basis following deal closing Learn more at www.driftwoodcapital.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
San Francisco Chronicle
20 minutes ago
- San Francisco Chronicle
Safeguard Scientifics: Q2 Earnings Snapshot
RADNOR, Pa. (AP) — RADNOR, Pa. (AP) — Safeguard Scientifics Inc. (SFES) on Thursday reported profit of $1.1 million in its second quarter. The Radnor, Pennsylvania-based company said it had net income of 7 cents per share. _____
New York Post
20 minutes ago
- New York Post
Costco won't sell abortion pills after outcry from religious groups
Costco said it will not offer abortion pills at any of its more than 500 pharmacies nationwide, a move celebrated by religious groups that lobbied against the drug being dispensed by retailers. The Washington state-based wholesaler insisted its decision was based on a lack of customer interest in the medication, Mifepristone, which together with another medicine called misoprostol, is used to end a pregnancy within 10 weeks of gestation. It didn't address whether pressure from conservative organizations influenced the move. 4 A Costco location in the US, one of more than 500 company pharmacies that will not provide Mifepristone. Getty Images A coalition of religious groups including Idaho-based Inspire Investing, the conservative legal organization Alliance Defending Freedom and treasurers and other financial officials from Ohio, Texas, Nevada and Utah had contacted the retailer last year requesting it not carry the drug, according to Bloomberg News. 'It's a very significant win and it's one we hope to build on this coming year,' said Michael Ross, an attorney working with Alliance Defending Freedom's corporate engagement division. Ross indicated the coalition plans to target Walgreens Boots Alliance and CVS next. Both pharmacy chains currently provide mifepristone in states that don't have abortion restrictions. People living in states that have severely limited abortion can obtain the medication by mail from states without such bans. The religious investors sent similar requests last year to Kroger, Walmart and Albertsons alongside Costco, urging them against carrying the medication. Kroger responded that it has never provided abortion pills and continues monitoring regulatory developments. Neither Walmart nor Albertsons currently stocks the medicine. Costco's decision intensifies the ongoing debate about access to the medication. 4 Mifepristone tablets are part of a two-drug regimen to terminate early pregnancies. AP New York City Comptroller Brad Lander had written to various retailers in July last year representing city pension funds, encouraging them to pursue authorization for offering the drug. 'Costco's decision to refuse to dispense mifepristone is disappointing and short-sighted,' a representative from Lander's office told Bloomberg. 'Failure to provide access to proven safe and FDA-approved medication under the guise of 'weak demand' risks isolating customers and undermines the company's credibility.' The Post has sought comment from Costco and Lander. The religious organizations have promised to continue to ramp up pressure. 'We have this momentum,' said Tim Schwarzenberger, who leads corporate engagement at Inspire, which manages the biggest religious exchange-traded fund. 'Now there is a chance to turn to some of the other retailers.' doesn't presently sell the medication, and Schwarzenberger indicated his organization will work to maintain that status. 4 A patient prepares to take mifepristone, which blocks progesterone to end an early-stage pregnancy. AP Amazon didn't provide a response to inquiries. Walgreens declined to comment but referenced information on its website stating: 'The US Supreme Court's ruling on mifepristone access allows Walgreens to continue to dispense mifepristone under the FDA guidelines.' CVS confirmed it distributes mifepristone in certain states where permitted after completing what it called a thorough certification procedure. 'We have a long history of supporting and advancing women's health and we remain focused on meeting their unique health needs. This includes providing access to safe, legal, and evidence-based reproductive health services,' the company stated. The elimination of nationwide abortion protections has resulted in uneven access throughout the US, leading telehealth providers to address some service gaps. Various state legislators have proposed legislation to designate mifepristone as a restricted drug and reduce telehealth availability. According to tracking by the Guttmacher Institute, a nonprofit research organization, lawmakers introduced 32 proposals to prohibit medication abortion and 38 to restrict access during the 2025 legislative period, representing the highest number since the overturn of Roe v. Wade. Data from the Society of Family Planning, an abortion rights organization, shows most abortions in America still occur either at medical facilities or through prescriptions from doctors filled at pharmacies like CVS or Walgreens. A smaller percentage involves prescriptions delivered by mail. 4 Anti-abortion demonstrators rally outside the US Supreme Court in March of last year as debate over medication abortion continues. AP Following increased state-level abortion restrictions, more women have pursued online mifepristone prescriptions for mail delivery. These shipments now represent approximately 25% of American abortions, up from 5 percent before the 2022 Supreme Court decision that ended federal abortion protections. Eight states permitting abortion have enacted protective legislation shielding doctors from prosecution when prescribing mifepristone to patients in states with abortion prohibitions. Ushma Upadhyay, a reproductive sciences professor at the University of California, San Francisco, explained that CVS, Walgreens and similar pharmacies don't provide the medication in states prohibiting abortion, creating difficulties for women seeking the procedure. Telehealth providers can utilize protective laws to ship pills directly to states with restrictions, she noted. This has generated legal disputes. A Texas resident filed a lawsuit in July against a California physician for prescribing abortion medication to his girlfriend. A New York doctor faces criminal charges in Louisiana and a lawsuit from Texas's Attorney General for shipping pills to patients in those states.
CNBC
an hour ago
- CNBC
3 charts that show Palantir's astronomical growth over the last five years
Palantir's astronomical rise since its public debut on the New York Stock Exchange in a 2020 direct listing has been nothing short of a whirlwind. Over nearly five years, the Denver-based company, whose cofounders include renowned venture capitalist Peter Thiel and current CEO Alex Karp, has surged more than 1,700%. At the same time, its valuation has broken new highs, dwarfing some of the world's technology behemoths with far greater revenues. The artificial intelligence-powered software company continued its ascent last week after posting its first quarter with more than $1 billion in revenue, reaching new highs and soaring past a $430 billion market valuation. Shares haven't been below $100 since April 2025. The stock last traded below $10 in May 2023, before beginning a steady climb higher. Retail investors are a key part of the stock's strength. Last month, retail poured $1.2 billion into Palantir stock, according to data from Goldman Sachs. Here's a closer look at Palantir's growth over the last five years and how the company compares to megacap peers. Government contracts have been one of Palantir's biggest growth areas since its inception. Last quarter, the company's U.S. government revenue grew 53% to $426 million. Government accounted for 55% of the company's total revenue but commercial is showing promise. Those revenues in the U.S. grew 93% last quarter, Palantir said. Still, one of the company's oldest customers is the U.S. Army. Earlier this month, the company inked a contract worth up to $10 billion for data and software to streamline efficiencies and meet growing military needs. In May, the Department of Defense boosted its agreement with Palantir for AI-powered battlefield capabilities by $795 million. "We still believe America is the leader of the free world, that the West is superior," Karp said on an earnings call earlier this month. "We have to fight for these values; we should give American corporations, and, most importantly, our government, an unfair advantage." The U.S. has been a key driver of Palantir's growth, especially as the company scoops up more contracts with the U.S. military. Palantir said the U.S. currently accounts for about three-quarters of total revenues. Commercial international revenues declined 3% last quarter and analysts have raised concerns about that segment's growth trajectory. Over the last five years, U.S. revenues have nearly quintupled from $156 million to about $733 million. Revenues outside the U.S. have doubled from about $133 million to $271 million. Palantir's market capitalization has rapidly ascended over the last year as investors bet on its AI tools, while its stock has soared nearly 500%. The meteoric rise placed Palantir among the top 10 U.S. tech firms and top 20 most valuable U.S. companies. But Palantir makes a fraction of the revenue of the companies in those lists. Last quarter, Palantir reported more than $1 billion in quarterly revenue for the first time, and its forward price-to-earnings ratio has surged past 280 times. By comparison, Apple and Microsoft posted revenue of $94 billion and $76 billion during the period, respectively, and carry a PE ratio of nearly 30 times. Forward PE is a valuation metric that compares a company's future earnings to its current share price. The higher the PE, the higher the growth expectations or the more overvalued the asset. A lower price-to-earnings ratio suggests slower growth or an undervalued asset. Most of the Magnificent Seven stocks, except for Nvidia and Tesla, have a forward PE that hovers around the 20s and 30s. Nvidia trades at more than 40 times forward earnings, while Tesla's sits at about 198 times. At these levels, investors are paying a jacked-up premium to own shares of one of the hottest AI stocks on Wall Street as its valuation has skyrocketed to astronomical heights. "This is a once-in-a-generation, truly anomalous quarter, and we're very proud," Karp said on an earnings call following Palantir's second-quarter results. "We're sorry that our haters are disappointed, but there are many more quarters to be disappointed."
